Clinical Trials Conducted by Okanagan Clinical Trials
Behavioural Medicine in Relation to the Gastrointestinal Tract (with D Campbell). Medical Research Council of Canada 1979-1980.
Behavioural Medicine and the Functional Bowel Disorders, Grant S07 RR05417, Division of Research Resources, National Institute of Health, 1980-1981.
A 10-Week Single-Blind Multicenter Study Evaluating the Efficacy and Tolerability of Paroxetine vs. Desipramine in the Treatment of Outpatients with Major Depression According to DSM-IIIR. Funded by Smith-Klein. 1992.
A 6-Month, Multi-centre, Double-Blind Comparison of the Tolerance and Efficacy of Sertraline and Fluoxetine in the Treatment of Major Depression. Funded by Pfizer Canada Inc., 1992-1993.
A 10-Week, Multi-centre, Double-blind Comparison of Sertraline and Desipramine in the Treatment of Major Depression in the Elderly. Funded by Pfizer Canada Inc., 1992-1993.
Controlled Dose Titration Study of the Efficacy and Tolerance of Sertraline (50, 100 mg) in the Treatment of Atypical Depression in Outpatients. Funded by Pfizer Canada Inc. 1993-1996.
A Double-blind, Placebo-Controlled, Comparison of Sertraline and Self-Administered Cognitive Behaviour Therapy, Alone or in Combination, in Panic Disorder. Funded by Pfizer Canada Inc., 1996-1999.
Investigation of Down-Titration Schedules of Haloperidol in Patients with Schizophrenia or Schizoaffective Disorder Initiating Therapy with Ziprasidone: An Open Six-Week Study. Funded by Pfizer Canada Inc., 1998-1999.
An Outcome Measurement Study in Schizophrenia. Funded by Synectics Health Corporation, 1999.
A Double-blind, Randomized, Placebo-Controlled Trial the Efficacy and Safety of Flexible Dosages Evaluating Lu 26-054 and Citalopram in Outpatients with Major Depressive Disorder. (99-003 Phase III) Funded by Lundbeck Canada Inc., 1999.
A Double-blind, Randomized, Placebo-Controlled Trial With Flexible Dosages Evaluating the Efficacy and Safety of Reboxetine vs Placebo Vs Paroxetine. Comparison in Patients with Major Depressive Disorder. (M20200046 Phase III) Funded by Pharmacia & Upjohn, 2000.
An open, long-term safety follow-up study of Lu 26-054 in the treatment of Major Depressive Disorder. (99-002 Phase III) Funded by Lundbeck Canada Inc., 1999-01.
A 52-Week Open-label Reboxetine Continuation Therapy. (950E-CNS-0005-087 Phase IV) Funded by Pharmacia and Upjohn, 2000-01.
A Double-blind, Placebo-Controlled, Parallel-Group, Flexible-Dose Study of Venlafaxine Extended-Release Capsules in Adult Outpatients with Panic Disorder. (0600B5-391-CA Phase III) Funded by Wyeth-Ayerst, 2000-01.
A Double-blind, Placebo-Controlled, Comparative Efficacy Study of Venlafaxine and Sertraline in Producing Remission in Outpatients with Major Depressive Disorder. (60081-402-CA Phase III) Funded by Wyeth-Ayerst, 2001.
A Double-blind, Placebo-Controlled, 3-arm dose study of Paroxetine CR intermittent dosing (12.5 mg and 25 mg) for Premenstrual Dysphoric Disorder. (29060-717 Phase III) Funded by GlaxoSmithKline, 2001.
A 6-Week, Double-blind, Randomized, Multicenter, Fixed Dose, Placebo-Controlled Study of Pagoclone dosed twice a day in Patients with Generalized Anxiety Disorder (CI-1043-012 Phase IIb/III). Funded by Pfizer, 2001.
A Double-blind, Placebo-Controlled, Parallel-Group, Flexible-Dose Study of Venlafaxine Extended-Release Capsules in Adult Outpatients with Panic Disorder. (0600B5-353-CA Phase III) Funded by Wyeth-Ayerst, 2001-02.
A Double-blind, Placebo-Controlled, Parallel-Group, Evaluation of the Long-term Safety, Efficacy, and Prevention of Relapse in Adult Outpatients with Panic Disorder who Respond to Open-Label Venlafaxine ER. (0600B5-354-CA) Funded by Wyeth-Ayerst, 2001-02.
A Randomized, Double-Blind, Placebo-Controlled, Single-Attack, Parallel-Group Evaluation of the Efficacy of Sumatriptan 100 mg tablets versus Placebo in the Treatment of Subjects who Affirm Tension, Tension-Type or Stress Headaches and who Meet International Headache Society Criteria for Migraine. (SUM 40312) Funded by GlaxoSmithKline, 2003.
An 8-week, Randomized, Double Blind, Parallel-Group, Placebo-Controlled, Multicenter, Fixed Dose Study Comparing the Efficacy and Safety of GW597599B or Paroxetine to Placebo in Moderately to Severely Depressed Patients with Major Depressive Disorder. (GSK NKD20006 Phase II). Funded by GlaxoSmithKline, 2003.
A 6-week, Randomized, Double Blind, Parallel-Group, Active and Placebo Controlled Study to Assess the Efficacy of R228060 in Adult Subjects with Major Depressive Disorder (MDD). (R228060-MDD-201 Phase IIa). Funded by Johnson and Johnson.
A Canadian Naturalistic Study of a community-based cohort treated for Bipolar disorder (CNS Bipolar), (Phase IV). Funded by Eli Lilly Canada, 2003.
A Canadian Multicenter, Double-blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Immediate-Release Formulation Quetiapine Fumarate (SeroquelR) in the Treatment of Subjects with Drug-Induced Psychosis in Parkinson's Disease. (Phase III) Funded by AstraZeneca, 2004.
A 6-week, Placebo and Paroxetine-Controlled, Double-Blind, Randomized, Parallel-Group, Fixed-Dose, Multicenter Study to evaluate the safety and efficacy of three doses of Ro67-5930 in the treatment of Major Depressive Disorder (MDD). (BN16568B, Phase II). Funded by F.Hoffmann-La Roche, 2003.
A multi-center, randomized, double-blind, parallel group trial to compare the efficacy and safety of fixed-dose rosiglitazone/glimepiride combination therapy to glimepiride monotherapy and rosiglitazone monotherapy in drug naïve subjects with type 2 diabetes mellitus. (Phase III). Funded by GlaxoSmithKline, 2004.
A double-blind, randomized, parallel-group, placebo controlled, 6-month study of Gaboxadol 15 mg fixed-dose in non-elderly outpatients with primary insomnia. (Phase III). Funded by Lundbeck Canada Inc., 2004.
A 6-week, Randomized, Double-Blind, Parallel-Group and Placebo-Controlled Study to Assess the Efficacy of R228060 in Adult Subjects with Major Depressive Disorder (MDD). (R228060-MDD-201 Phase IIa). Funded by Jansen Ortho, 2004.
A multi-center, randomized, double-blind, dose-response, placebo and gabapentin controlled study of PD-217,014 in the treatment of postherpetic neuralgia. (Phase II). Funded by Pfizer Ltd., 2004.
LOGIC: Longitudinal Outcomes study of GastroIntestinal symptoms (abdominal pain, bloating, constipation) in Canada, (Phase IV), Funded by Novartis Pharmaceutical Canada Inc., 2004.
A Phase III, 12-week, Multicenter Double-blind, double-dummy, Randomized, Placebo and Active Comparator-controlled, Parallel Group study to investigate the Efficacy and Safety of GW406381 1mg, 5mg, 10mg, 25 mg and 50 mg, administered orally once daily, in adults with Osteoarthritis of the knee. Funded by GlaxoSmithKline, 2005.
A double-blind, randomized, placebo-controlled, parallel-group, phase III study evaluating the efficacy and safety of gaboxadol 5 mg and 10 mg daily in elderly outpatients with primary insomnia. Funded by Lundbeck, 2005
A 12-month phase III safety study of gaboxadol 10 mg daily consisting of a 6-month double-blind, randomized, placebo-controlled, parallel-group period followed by a 6-month open-label period in elderly outpatients with primary insomnia. Funded by Lundbeck, 2005
CanACTFAST: CANadians Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration. A Canadian, multicenter, twelve-week, single-step titration, open-label study assessing the percentage of dyslipidemic patients achieving low density lipoprotein cholesterol (LDL-C) targets with atorvastatin starting doses of 10mg, 20mg, 40mg, and 80mg. (Phase IV) Funded by Pfizer, 2005.
Phase III Randomized, Double Blind, Placebo-Controlled Induction Study of Sargramostim (Leukine) in Patients with Active Crohn's Disease. Funded by Berlex, 2005.
An Eight-week, Multicenter, Double-blind, Placebo-Controlled Study Evaluating the Efficacy, Safety and Tolerability of One Fixed 100mg Dose of Saredutant in Patients with Major Depressive Disorder. (Phase III). Funded by Sanofi, 2005.
A 3-Month, Open-Label Study of Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder; Symptomatic and Functional Outcomes. (Phase IV) Funded by Eli Lilly, 2005.
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults taking Opioid Therapy for Persistent Non-Cancer Pain. (Phase III). funded by GlaxoSmithKline, 2006.
A multicenter, randomized, double blind, placebo controlled, phase 3 trial to evaluate the efficacy and safety of saxagliptin (MBS 477118) as a monotherapy in subjects with type 2 diabetes who have inadequate glycemic control with diet and exercise. Funded by Bristol Myers Squibb, 2006.
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Long-Term Safety of Alvimopan 0.5mg Twice Daily for 12 Months for the Treatment of Opioid-Induced Bowel Dysfunction in Adults taking Opioid Therapy for Persistent Non-Cancer Pain. (Phase III), funded by GlaxoSmithKline, 2006.
A multicenter, randomized, double blind, placebo controlled, phase 3 trial to evaluate the efficacy and safety of saxagliptin (MBS 477118) in combination with metformin in subjects with type 2 diabetes who have inadequate glycemic control on metformin alone. Funded by Bristol Myers Squibb, 2006.
A randomized, double-blind, placebo controlled, parallel group study of the efficacy, safety and tolerability of XBD173 in patients with Generalized Anxiety Disorder. (Phase III) Funded by Novartis, 2006.
A Multicenter, Randomized, Double-Blind, Active Controlled Study to Compare the Long-Term Effect (up to 5 years) of Treatment with LAF bid to Glimepiride up to 6 mg Daily as Add-On Therapy in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy. (Phase III) Funded by Novartis, 2006.
A Randomized, Double Blind, Parallel-Group, Placebo-Controlled, Forced Dose Titration Study Evaluating the Efficacy and Safety of GW679769 and Paroxetine in Subjects with Social Anxiety Disorder. (Phase II) Funded by GlaxoSmithKline, 2006.
A Multicenter, Randomized, double-blind, placebo-controlled Study of a Combination of Levonorgestrel and Ethinyl Estradiol in a Continuous Daily Regimen in Subjects with Premenstrual Dysphoric Disorder. (Phase III) Funded by Wyeth, 2006.
NAVIGADE-An open multicentre prospective naturalistic phase IV investigation of the outcome of depressed patients treated with escitalopram in Canada. Funded by Lundbeck, 2006.
An International, Multi-Centre, Double-blind, Randomized, Parallel-group, Placebo-controlled, Phase III study of the Efficacy and Safety of Quetiapine Fumarate (Seroquel, single oral 300 mg or 600 mg dose) and Lithium as Monotherapy in Adult Patients with Bipolar Depression for 8 weeks and Quetiapine in Continuation Treatment for 26 up to 52 weeks. Funded by AstraZeneca, 2006.
An 8-Week, Multicenter, Randomized, Double-blind, Placebo controlled, Flexible dose study of Pregabalin (300-600mg/day) and Venlafaxine XR (75-225mg/per day) for the acute treatment of DSM-IV Generalized Anxiety Disorder in outpatients. (Phase IIIb) Funded by Pfizer, 2006.
An observational study to characterize the burden of illness associated with laxative use in subjects using opioids for the management of persistent pain. (Phase IV) Funded by GlaxoSmithKline, 2006.
An eight-week, double-blind, placebo controlled, multicenter study with escitalopram (10 mg qd) as positive control, evaluating the efficacy, safety, tolerability of a fixed dose of SR58611A (350 mg q12) in outpatients with Major Depressive Disorder (MDD). (Phase II) Funded by sanofi aventis, 2006.
A comparison of duloxetine hydrochloride, venlafaxine extended release, and placebo in the treatment of generalized anxiety disorder. (Phase III) Funded by Eli Lily, 2006.
A Multi-Centre, Double-Blind, Randomized, Parallel Group, Placebo-Controlled and Active Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SRT) as Mono-Therapy in the Treatment of Adult Patients with Major Depressive Disorder. Funded by AstraZeneca, 2007.
An International, Multi-Centre, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Controlled Study of the Efficacy and Safety of Sustained-Realease Quetiapine Fumarate (Seroquel SR) in the Treatment of Generalized Anxiety Disorder. (Phase III) Funded by AstraZeneca 2007.
A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD). (Phase II) Funded by GlaxoSmithKline, 2007
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Licarbazepine 750-2500mg/d Combined With Lithium or Valproate in the Treatment of Manic Episodes of Bipolar I Disorder Over 6 Weeks. (Phase III) Funded by Novartis, 2007.
A 14-Week, Randomized, Double-Blind, Placebo-Controlled Trial of Pregablin Twice Daily in Patients With Fibromyalgia. (Phase III) Funded by Pfizer, 2007.
A 12-Week, Open-Label, Safety Trial of Pregablin in Patients with Fibromyalgia. (Phase III) Funded by Pfizer, 2007.
[S,S] Reboxetine Add On Trial: A Randomized, Double Blind, Placebo-Controlled, Multi-Center Study of [S,S]-Reboxetine in Patients with Postherpetic Neuralgia (PHN) Concomitantly with Pregablin. (Phase III) Funded by Pfizer, 2007.
An Eight-Week, Multicenter, Double-Blind, Placebo and Paroxetine-Controlled Study Evaluating the Efficacy and Tolerability of Two Fixed Doses of SSR149145 (250mg bid and 100mg bid) in Patients with Major Depressive Disorder. (Phase II/III) Funded by Sanofi, 2007.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects with moderate to severe Crohn's disease. (Phase III) Funded by Abbott, 2007.
Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Oral MOA-728 for the Treatment of Opioid Induced Bowel Dysfunction in Subjects with Chronic Malignant Pain. (Phase II) Funded by Wyeth, 2007.
A Multi-Centre, Open-Label, Parallel Group, Randomized, Flexible Dose Study to Evaluate the Safety and Tolerability of Switching from Existing Atypical Antipsychotics to Bifeprunox in Subjects with Schizophrenia or Schizoaffective Disorder. (Phase IIIb) Funded by Solvay Pharmaceutical, 2007.
A Randomized, Double-Blind, Two Arm Study Comparing the Efficacy and Safety of Trazodone Contramid OAD and Placebo in the Treatment of Unipolar Major Depressive Disorder. (Phase III) Funded by Labopharm, 2007.
A Randomized, Multi-Centre, Double-Blind, Parallel-Group Study to Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenia Patients. (Phase IIIb) Funded by Solvay Pharmaceutical, 2007.
A Multi-Centre, Open-Label, Treatment Protocol of the Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects with Moderate to Severe Crohn’s Disease (ACCESS). (Phase III) Funded by Abbott, 2007.
Reboxetine Add-On Trial: A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study of [S,S]-Reboxetine in Patients with Postherpetic Neuralgia (PHN) Concomitantly Treated with Pregabalin. (Phase II) Funded by Pfizer, 2007.
A Randomized, Placebo-Controlled Trial of the Efficacy and Safety of Pregabalin in the Treatment of Subjects with Peripheral Neuropathic Pain. (Phase IIIb) Funded by Pfizer, 2007.
Attributes of Response in Depression Patients Switched to Treatment with Duloxetine (ARDENT Study). A phase 4, multicenter, single-arm, open-label trail with four study periods that will evaluate the duloxetine in patients with MDD who have failed to respond to one course of treatment with an SSRI or SNRI. (Phase IV) Funded by Eli Lily, 2008.
A multicenter, randomized, double-blind, placebo-controlled, dose-tolerability titration study to evaluate the efficacy and safety of perampanel (E2007) i patients with post-herpetic neuralgia (PHN). (Phase II) Funded by Eisai, 2008.
A phase IIb randomized, double blind, placebo controlled, dose ranging, multi-center study to determine the safety, tolerance and efficacy of AT-1001 in Celiac Disease subjects during a gluten challenge. (Phase IIb) Funded by Alba Therapeutics, 2008.
A multi-center, long term, open label study of [S,S] Reboxetine (PNU-165442G) Administered once daily in patients with fibromyalgia. (Phase III) Funded by Pfizer, 2008.
An Eight Week, Multi-Centre, Randomized, Double-Blind, Placebo-Controlled Study With Escitalopram as an Active Control to Evaluate the Efficacy, Safety, and Tolerability of a Saredutant 100mg Dose Once Daily in Patients with Generalized Anxiety Disorder. Funded by Sanofi Aventis, 2006-2008.
An 8-week International, Multicentre, Double-blind, Randomised, Parallel-group, Placebo-controlled, Phase III Study of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Sustained-release administered once daily as Monotherapy in the treatment of Adult Patients with Acute Bipolar Depression (JUNIPER Study). (Phase III) Funded by AstraZeneca, 2007.
A Multi-Centre, Open-Label, Parallel-Group, Randomized, Flexible Dose Study to Evaluate the Safety and Tolerability of Switching from Existing Atypical Antipsychotics to Bifeprunox in Subjects with Schizophrenia or Schizoaffective Disorder. Funded by Solvay Pharmaceutical, 2007-2008.
A Ten-Week, Multi-Centre, Randomized, Double-Blind, Placebo and Active Controlled, Parallel-Group, Flexible-Dose Study Evaluating the Efficacy, Safety and Tolerability of GSK372475 (1.5mg/day to 2.0mg/day) or Extended Release Venlafaxine XR (150mg/day to 225mg/day) Compared to Placebo in Adult Subjects Diagnosed with Major Depressive Disorder. Funded by GlaxoSmithKline, 2007-2008.
A Placebo Controlled Randomized, 12-Week, Dose-Ranging, Double-Blind Study Versus Placebo using Tolterodine as a Study Calibrator to Evaluate Efficacy and Safety of SSR240600C in Women with Overactive Bladder Including Urge Urinary Incontinence. Funded by Sanofi Aventis, 2007-2009.
A Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter, Outpatient Trial of PD0200390 in Adults with Primary Insomnia. Funded by Pfizer, 2007-2009.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Combination with Metformin in Subjects with Type 2 Diabetes who have Inadequate Glycemic Control on Metformin Alone. (Phase III) Funded by BMS, 2007.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control with Diet and Exercise. (Phase III) Funded by BMS, 2007.
A 6-Week, Randomized, Double-Blind, Placebo-Controlled Study of XXX 80mg q.d. and 80mg t.i.d. in the Treatment of Adults with Major Depressive Disorder and Concomitant Anxiety. Funded by BrainCells Inc, 2007.
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Duloxetine-Referenced, Fixed-Dose Study Evaluating the Efficacy and Safety of Three Dosages of Lu AA21004, in Acute Treatment of Major Depressive Disorder. Funded by Lundbeck, 2008.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of AVONEX® in Subjects with Moderate to Severe Ulcerative Colitis. Funded by Biogen Idec Inc., 2008.
A Phase IIIb, Multinational, Randomized, Double-Blind, Placebo-Controlled Trial to Access the Efficacy and Safety of Certolizumab Pegol, a Pegylated Fab’ Fragment of a Humanized Anti-TNF-Alpha Monoclonal Antibody, Administered Subcutaneously at Weeks 0, 2 and 4 in Subjects with Moderately to Severely Active Crohn’s Disease.(Phase IIIb) Funded by UCB, 2008-2009.
A Phase IIIb, Multinational, Open-Label, Follow-On Trial to C87085 Designed to Assess the Long-Term Safety of Certolizumab Pegol, a Pegylated Fab’ Fragment of a Humanized Anti-TNF-Alpha Monoclonal Antibody, Administered at Weeks 0, 2 and 4, and then Every 4 Weeks Thereafter, in Subjects with Moderately to Severely Active Crohn’s Disease Who Have Participated in Study C87085. (Phase IIIb) Funded by UCB, 2008-2009.
A 5-Year Registry Study of Humira® (Adalimumab) in Subjects with Moderately to Severely Active Crohn’s Disease (CD). Funded by Abbott, 2008.
A 24-Week, International, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Phase III Study, with a 24-Week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Patients with Type 2 Diabetes with Inadequate Glycemic Control on Insulin. (Phase III) Funded by AstraZeneca, 2008.
A Multicenter, Open Label Extension Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of E2007 (Perampanel) in Patients with Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN). Funded by Eisai, 2008.
A Multicenter, Randomized, Double-blind, Placebo-controlled 52-Week Study of the Human Anti-TNF Monoclonal Antibody Adalimubab for the Induction and Maintenance of Clinical Remission in Subjects with Moderately to Severely Active Ulcerative Colitis. Funded by Abbott, 2008.
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women. (Phase III) Funded by Biosante, 2009.
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Long Term Safety and Efficacy of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women. (Phase III) Funded by Biosante, 2009.
Optimization of Treatment with Infliximab in a Medical Setting (OPTIMIST) to determine the efficacy of Infliximab treatment-optimization in achieving a clinical response in Crohn's disease subjects with worsening symptoms despite maintenance IFX therapy. Funded by Shering Plough, 2009.
A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Functional Outcome in Patients with Major Depressive Disorder Treated with Desvenlafaxine Succinate Sustained Release. Funded by Wyeth, 2009.
A Double-Blind, Efficacy and Safety Study of Duloxetine versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder. Funded by Eli-Lilly, 2009.
A Fixed-Dose, Randomized, Double-Blind, Placebo-Controlled Study of LY2216684 in Pediatric Patients with Attention Deficit/Hyperactivity Disorder. Funded by Eli Lilly, 2009.
A Phase 3 Open-Label Flexible Dosing Study of LY2216684 in Paediatric Patients with Attention Deficit/Hyperactivity Disorder to Assess the Safety and Efficacy of LY2216684 during 5 Years of Active Treatment. (Phase III) Funded by Eli Lilly, 2009.
A Multicentre, Double Blind, Placebo Controlled, Randomized Withdrawal, Parallel Group Study to Evaluate the Efficacy and Safety of 50 mg/day of DVS SR in Adult Outpatients with Major Depressive Disorder. Funded by Wyeth, 2009.
An Open-Label Study to Evaluate the Long-term Safety of Subcutaneous MOA-728 for Treatment of Opioid-Induced Constipation in Subjects with Non-Malignant Pain. Funded by Wyeth, 2009.
designed by growmedia.